Logo Icon
OrthoLength Pro Clinical & Patient Community
Log in Register
MEDICAL DISCLAIMER: The information provided on OrthoLength Pro is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified orthopedic surgeon.
Fact Checked by Clinical Team Study Summary

Hip Replacement Safety

Ta
Taheriazam A, Poursaleh E, Abb...
January 01, 2025
0 views
View on PubMed
6 min read 1,054 words hip replacement safety Medically Reviewed

Overview

Total hip arthroplasty (THA) is a common procedure for treating severe DDH, especially Crowe Type 4, which involves complete hip dislocation and acetabular deficiency. This study examined the incidence of nerve injury in patients undergoing THA via trochanteric osteotomy and proximal femoral shortening, with a focus on the impact of prosthesis type (cemented vs. cementless) on nerve palsy. The primary topic of THA is crucial for patients with severe hip dysplasia, as it can significantly improve their quality of life.

What This Study Examined

The study aimed to evaluate the incidence of nerve injury in patients with Crowe Type 4 DDH who underwent THA using trochanteric osteotomy and proximal femoral shortening. The researchers also investigated the effect of prosthesis type on the risk of nerve palsy, which is a significant complication of THA. The study's findings can help inform patients and surgeons about the benefits and risks of different prosthesis types in THA procedures.

Why This Matters for Patients

Understanding the risks and benefits of THA is essential for patients with severe DDH. Nerve palsy is a potential complication of THA that can result in significant disability and decreased quality of life. By knowing the incidence of nerve injury and the factors that contribute to it, patients can make informed decisions about their treatment options and discuss their concerns with their surgeons.

Medical Background

DDH is a condition where the hip joint doesn't form properly, leading to dislocation and arthritis. Crowe Type 4 DDH is a severe form of the condition, characterized by complete hip dislocation and acetabular deficiency. THA is a surgical procedure that involves replacing the damaged hip joint with an artificial one, which can help alleviate pain and improve mobility.

How the Procedure Works

THA typically involves a direct lateral approach, where the surgeon makes an incision in the hip to access the joint. Trochanteric osteotomy, which involves cutting the trochanter (a part of the femur), is sometimes performed to facilitate the procedure. Proximal femoral shortening, which involves shortening the femur, may also be necessary to accommodate the artificial joint. The procedure can be performed using either cemented or cementless prostheses, which have different fixation methods and materials.

Who Is a Candidate?

Candidates for THA typically have severe DDH or other hip conditions that cause significant pain and disability. Patients with Crowe Type 4 DDH may benefit from THA using trochanteric osteotomy and proximal femoral shortening, which can help improve their hip function and quality of life.

Clinical Summary

  • Procedure: Total hip arthroplasty (THA) using trochanteric osteotomy and proximal femoral shortening
  • Typical Duration: 1-2 hours
  • Recovery: 6-12 weeks
  • Success Rate (general): 90-95% for pain relief and improved mobility

Study Methodology

The study was a prospective cohort study that involved 62 patients (81 hips) with Crowe Type 4 DDH. The patients underwent THA using trochanteric osteotomy and proximal femoral shortening, with either cemented or cementless prostheses. The researchers assessed nerve injury using electromyography (EMG) and nerve conduction velocity (NCV) tests.

Patient Selection Criteria

Patient selection criteria included a diagnosis of Crowe Type 4 DDH and the need for THA using trochanteric osteotomy and proximal femoral shortening. Patients with other hip conditions or those who had previously undergone hip surgery were excluded from the study.

Outcome Measures

The primary outcome measure was the incidence of nerve injury, which was assessed using EMG and NCV tests. Secondary outcome measures included the impact of prosthesis type on nerve palsy and the overall success rate of the procedure.

Results & Findings

The study found that 59 cases (95.2%) had no neurological deficit, while 3 cases (4.8%) developed neurological problems during the 12-month follow-up period. The frequency of neurological deficit had a statistically significant correlation with the type of prosthesis (P = 0.01), with cementless prostheses demonstrating superior neurological safety.

Key Outcomes

The key outcomes of the study included a low incidence of nerve injury and a significant correlation between prosthesis type and neurological safety. The study's findings suggest that cementless prostheses may be a better option for patients undergoing THA using trochanteric osteotomy and proximal femoral shortening.

Complications & Risks

Complications and risks associated with THA include nerve palsy, infection, and prosthesis failure. The study found that nerve palsy was a significant complication, but the incidence was low (4.8%). Patients should discuss their individual risks and concerns with their surgeons before undergoing the procedure.

Key Takeaways for Patients

  • Total hip arthroplasty (THA) using trochanteric osteotomy and proximal femoral shortening can be an effective treatment option for Crowe Type 4 DDH.
  • Cementless prostheses may be a better option for patients undergoing THA due to their superior neurological safety.
  • Patient selection and careful planning are crucial to minimizing the risk of complications and ensuring a successful outcome.
  • Patients should discuss their individual risks and concerns with their surgeons before undergoing the procedure.

Patient questions to ask their surgeon include: What type of prosthesis will be used? What are the potential risks and complications of the procedure? What is the expected recovery time and rehabilitation process?

Frequently Asked Questions

What is Crowe Type 4 developmental dysplasia of the hip?
Crowe Type 4 DDH is a severe form of hip dysplasia characterized by complete hip dislocation and acetabular deficiency. It can cause significant pain and disability, and may require surgical intervention.
What is total hip arthroplasty (THA)?
THA is a surgical procedure that involves replacing the damaged hip joint with an artificial one. It can help alleviate pain and improve mobility in patients with severe hip conditions.
What is trochanteric osteotomy?
Trochanteric osteotomy is a surgical procedure that involves cutting the trochanter (a part of the femur) to facilitate THA or other hip surgeries. It can help improve access to the hip joint and facilitate the placement of the artificial joint.
What are the risks and complications of THA?
The risks and complications of THA include nerve palsy, infection, and prosthesis failure. Patients should discuss their individual risks and concerns with their surgeons before undergoing the procedure.
How long does it take to recover from THA?
The recovery time for THA can vary depending on the individual patient and the specifics of the procedure. Typically, patients can expect to spend 6-12 weeks recovering from the surgery and undergoing rehabilitation.

(Source: PubMed / Europe PMC)

More on: hip replacement safety Last reviewed: August 2, 2026

Community Disclaimer

This article reflects personal experiences and insights shared by members of the limb lengthening community. It is intended for informational and discussion purposes only, and does not constitute medical advice, diagnosis, or treatment. Individual experiences may vary. Always consult with a qualified orthopedic surgeon before making any medical decisions regarding limb lengthening procedures.

Explore Related Research

Clinical Insight

Limb Lengthening After Hip Replacement

Overview Limb lengthening is a surgical procedure used to treat limb length discrepancy (LLD), which can occur after a total hip arthroplasty (THA). This condition can lead to back pain, disordered gait, and decreased functional outcomes. A recent study published on PubMed (Source: PubMed) examined the technique and results of using a retrograde motorized intramedullary lengthening nail (MILN) to lengthen the femur after a THA. This study is significant because it provides insight into a distraction osteogenesis technique that can help patients with LLD after THA. The study's findings can help inform patients and surgeons about the safety and efficacy of this procedure. What This Study Examined The study examined the outcomes of 11 patients who underwent limb lengthening using a retrograde MILN after a THA. The study looked at the etiology of the LLD, the magnitude of the length discrepancy, and the complications that occurred during and after the procedure. Why This Matters for Patients This study matters for patients because it provides evidence that limb lengthening using a retrograde MILN is a safe and effective option for treating LLD after THA. This can help patients make informed decisions about their treatment options and can provide reassurance about the potential outcomes of the procedure. Medical Background Limb lengthening is a surgical procedure that is used to treat LLD. It involves the use of an intramedullary nail or an external fixator to gradually lengthen the bone. This can be done using a variety of techniques, including osteotomy and callotasis. How the Procedure Works The procedure involves the insertion of a retrograde MILN into the femur, which is then used to gradually lengthen the bone. The nail is inserted through the distal femur and is then attached to a lengthening device. The lengthening device is then used to gradually lengthen the bone over a period of time. Who Is a Candidate? Candidates for limb lengthening using a retrograde MILN include patients who have LLD after a THA and who are looking for a hip-sparing option. Patients who have bone regeneration issues or who have osteoporosis may not be good candidates for this procedure. Clinical Summary Procedure: Limb lengthening using a retrograde MILN Typical Duration: Several months to a year or more, depending on the length of the bone to be lengthened Recovery: Several months to a year or more, depending on the individual patient and the extent of the procedure Success Rate (general): High, but depends on the individual patient and the extent of the procedure Study Methodology The study was a retrospective review of 11 patients who underwent limb lengthening using a retrograde MILN after a THA. The patients were followed for a mean of 12 months after the procedure, and the outcomes were evaluated using radiographic and clinical assessments. Patient Selection Criteria The patients were selected based on their etiology of LLD, the magnitude of the length discrepancy, and their overall health status. The patients who were included in the study had a mean age of 45 years and a mean length discrepancy of 35 mm. Outcome Measures The outcomes were evaluated using radiographic and clinical assessments. The time to union was also evaluated, as well as the complication rate. Results & Findings The study found that the mean lengthening was 35.7 mm, and the mean time to union was 1.5 months per cm of lengthening. The study also found that there were no adverse effects on the THA function, and that the complication rate was low. Key Outcomes The key outcomes of the study were that limb lengthening using a retrograde MILN is a safe and effective option for treating LLD after THA. The study also found that the time to union was relatively short, and that the complication rate was low. Complications & Risks The study found that there were two patients who required reamed exchange nailing to achieve union, and one patient who experienced an interprosthetic fracture that was treated with removal of the MILN and plate fixation. Key Takeaways for Patients Limb lengthening using a retrograde MILN is a safe and effective option for treating LLD after THA. The procedure can help to improve functional outcomes and reduce back pain. Patients should discuss the potential risks and benefits of the procedure with their surgeon, including the risk of adverse effects on the THA function. Patients should ask their surgeon about the time to union and the complication rate for the procedure. Frequently Asked Questions What is limb lengthening using a retrograde MILN? Limb lengthening using a retrograde MILN is a surgical procedure that involves the use of a retrograde motorized intramedullary lengthening nail (MILN) to lengthen the femur after a THA. The procedure is used to treat limb length discrepancy (LLD) and can help to improve functional outcomes and reduce back pain. How long does the procedure take? The procedure can take several months to a year or more to complete, depending on the length of the bone to be lengthened and the individual patient's healing rate. What are the risks and complications of the procedure? The risks and complications of the procedure include adverse effects on the THA function, interprosthetic fracture, and reamed exchange nailing. Patients should discuss the potential risks and benefits of the procedure with their surgeon. How long does it take to recover from the procedure? The recovery time for the procedure can vary depending on the individual patient and the extent of the procedure. Patients can expect to spend several months to a year or more recovering from the procedure, and may need to use assistive devices such as crutches or a walker during the recovery period. Is limb lengthening using a retrograde MILN a new procedure? No, limb lengthening using a retrograde MILN is not a new procedure. However, the use of this specific type of nail and the technique used to lengthen the bone are relatively new and are still being studied and refined. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →
Clinical Insight

Trochanteric-Entry Intramedullary Lengthening Nails in Growing Children: Safety Profile and Clinical Implications

Overview Limb lengthening, also known as distraction osteogenesis, is a surgical procedure used to treat limb length discrepancies. One common method of limb lengthening is through the use of intramedullary nails, such as the Precice™ nail. Recently, a study examined the safety of trochanteric-entry intramedullary lengthening nails in skeletally immature patients (Source: PubMed). This study is significant because it sheds light on the potential risks and benefits of this procedure in younger patients. The study focused on patients with more than 2 years of growth remaining, which is crucial because this population is at a higher risk of proximal femoral growth disturbance, including coxa valga. The researchers aimed to evaluate the proximal femoral morphology following trochanteric-entry intramedullary lengthening in these patients. The findings of this study are essential for patients, parents, and healthcare providers who are considering this procedure. What This Study Examined The study examined the safety of trochanteric-entry intramedullary lengthening nails in skeletally immature patients. Specifically, it looked at the radiographic parameters, including the NSA, mLPFA, and ATD, before and after the procedure. Why This Matters for Patients This study matters for patients because it provides insight into the potential risks and benefits of trochanteric-entry intramedullary lengthening nails. The results can help patients and their families make informed decisions about their treatment options. Additionally, the study's findings can inform healthcare providers about the best practices for this procedure and how to minimize potential complications. Medical Background Limb lengthening is a surgical procedure that involves cutting and slowly lengthening the bone to treat limb length discrepancies. This can be achieved through various methods, including external fixation, internal lengthening nails, or a combination of both. The Precice™ nail is an example of an intramedullary nail used for femoral lengthening. How the Procedure Works The procedure involves inserting an intramedullary nail into the femur (thigh bone) through an incision in the hip. The nail is then lengthened over time using an external controller, which gradually separates the bone segments. This process, known as distraction osteogenesis, allows for new bone growth and lengthening of the limb. Who Is a Candidate? Candidates for limb lengthening surgery typically have a significant limb length discrepancy, which can be congenital or acquired due to injury or illness. The procedure is often performed on patients with conditions such as achondroplasia, fibular hemimelia, or CPT. In growing children, the timing of surgery must consider remaining growth potential, hormonal status, and the risk of growth‑plate disturbance. Clinical Summary Procedure: Trochanteric-entry intramedullary lengthening nail insertion Typical Duration: Several months to several years, depending on the lengthening required Recovery: Varied, but typically involves a period of partial weight‑bearing and physical therapy Success Rate (general): High, but depends on individual patient factors and the expertise of the healthcare provider Study Methodology The study was a retrospective, institutional review board‑approved case series conducted at a single tertiary pediatric orthopedic center. Inclusion criteria were: Skeletally immature patients (open physes) with at least 2 years of growth remaining as estimated by the Green‑Anderson growth‑remaining chart. Underwent antegrade femoral lengthening with a Precice™ magnetically driven nail between January 2017 and December 2024. Minimum postoperative radiographic follow‑up of 12 months. Patients with prior femoral pathology, infection, or previous hip surgery were excluded. All surgeries utilized a standard trochanteric entry point, positioned at the lateral aspect of the greater trochanter. The nail was inserted under fluoroscopic guidance, and the lengthening protocol was programmed to achieve 1 mm of distraction per day after a 7‑day latency period. Radiographic assessments were performed pre‑operatively, immediately post‑operatively, and at final follow‑up. The primary outcomes included changes in: Neck‑shaft angle (NSA) – measured on an anteroposterior pelvis radiograph. Mechanical lateral proximal femoral angle (mLPFA) – the angle between the mechanical femoral axis and the proximal femoral line. Articulotrochanteric distance (ATD) – the vertical distance from the femoral head centre to the tip of the greater trochanter. Clinically meaningful coxa valga was defined as an increase in NSA of ≥2 standard deviations (≈ 5°) from baseline. Linear regression analyses evaluated the relationship between remaining growth (years until predicted skeletal maturity) and postoperative changes in the measured parameters. Statistical analysis employed SPSS® version 28.0. Continuous variables are reported as mean ± standard deviation; categorical variables as counts and percentages. A p‑value 2 years of growth remaining, with a low incidence of proximal femoral growth disturbance. Clinical Implications These findings have several practical ramifications for orthopedic surgeons, patients, and families: Safety in the majority of growing children: For patients with at least two years of anticipated growth, the risk of clinically significant coxa valga or other proximal femoral deformities appears minimal. Age‑specific risk stratification: Children younger than 9 years, particularly those with >4 years of growth remaining, may warrant closer radiographic monitoring because the study identified a trend toward valgus change proportional to remaining growth. Surveillance protocol: A reasonable follow‑up schedule includes radiographs at 3, 6, 12, and 24 months post‑operation, with additional imaging if the patient reports hip pain or demonstrates gait changes. Counselling for families: When discussing treatment options, clinicians can reassure families that infection and osteonecrosis were not observed in this series, but they should also explain the small possibility of valgus progression, especially in very young patients. Decision‑making for timing of surgery: In cases where the discrepancy is modest and the child is very young, clinicians may consider delaying definitive lengthening until closer to skeletal maturity, using alternative methods (e.g., temporary external fixation) in the interim. Ultimately, the study supports the continued use of trochanteric-entry intramedullary nails as a reliable option for limb lengthening in skeletally immature patients, provided that a structured radiographic surveillance plan is in place. Frequently Asked Questions Q: What is coxa valga and why is it a concern after femoral lengthening? A: Coxa valga refers to an increased neck‑shaft angle of the femur, which can alter hip biomechanics, potentially leading to gait abnormalities, accelerated joint wear, or increased risk of hip dislocation. Monitoring the NSA after lengthening helps detect early valgus changes. Q: How does a trochanteric‑entry nail differ from a retrograde or lateral entry nail? A: Trochanteric entry involves inserting the nail through the greater trochanter, preserving the distal femoral physis and allowing a more natural lengthening vector. Retrograde nails are placed from the distal femur and risk injury to the distal growth plate, while lateral entry can be more technically demanding in small children. Q: Are there specific activities that should be avoided after surgery? A: Patients are typically instructed to avoid high‑impact sports (e.g., running, jumping) for the first 6‑12 weeks, adhere to weight‑bearing restrictions set by the surgeon, and engage in a supervised physical‑therapy program to maintain joint range of motion. Q: What signs would indicate a need for earlier radiographic evaluation? A: New onset hip or groin pain, noticeable limp, asymmetry in limb length, or any change in gait symmetry should prompt an earlier X‑ray to assess for unexpected proximal femoral changes. Q: If a child develops progressive coxa valga, what are the treatment options? A: Mild valga may be managed with observation if functional outcomes are acceptable. More pronounced deformities can be addressed surgically with guided growth (temporary hemiepiphysiodesis) or corrective osteotomy, depending on severity and the child's remaining growth. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →
Clinical Insight

Brown Algae Ingredients in Skincare: Safety Guide for Patients

Overview Recent research by the Expert Panel for Cosmetic Ingredient Safety examined the safety of brown algae‑derived substances used in everyday cosmetics. Among the 82 brown‑algae ingredients listed in the International Cosmetic Ingredient Dictionary, the panel determined that 68 are safe at current concentrations, while data were insufficient for the remaining ones. This analysis matters because many moisturizers, sunscreens, and anti‑aging products contain these marine‑derived compounds, and patients often wonder whether they can trust the labels on their favorite skin‑care items. Understanding the scientific assessment helps consumers make informed choices, especially those with sensitive skin, allergies, or concerns about heavy‑metal contaminants such as arsenic. The findings also guide manufacturers in applying good manufacturing practices to limit possible impurities. What This Study Examined The panel reviewed the toxicology, exposure levels, and impurity profiles of brown algae‑derived ingredients that function primarily as skin‑conditioning agents. The assessment considered published peer‑reviewed data, industry reports, and regulatory submissions to decide whether each ingredient is safe for cosmetic use under typical conditions. Why This Matters for Patients Cosmetic products are applied directly to the skin, often daily and for years, so any hidden risks could accumulate over time. Knowing that 68 ingredients have been deemed safe reassures users, while the uncertainty surrounding the remaining 14 highlights the importance of reading labels, checking for third‑party testing, and discussing concerns with dermatologists. Medical Background Brown algae, also known as Phaeophyceae, are a rich source of polysaccharides, polyphenols, and lipids that are attractive for skin‑care formulations. These compounds can act as moisturizers, antioxidants, and anti‑inflammatory agents. However, during harvesting and processing, trace amounts of environmental contaminants—most notably arsenic—may be introduced. Because cosmetics are regulated differently from pharmaceuticals, the safety threshold for each ingredient depends on both its intrinsic toxicity and the concentration at which it is used in a product. The panel’s safety conclusions rely on the principle that if an ingredient’s exposure remains below the established no‑observed‑adverse‑effect level (NOAEL), it is unlikely to cause harm. How the Procedure Works In the context of cosmetics, “procedure” refers to the manufacturing steps that transform raw brown algae into usable ingredients. First, the algae are harvested, washed, and dried. Extraction methods—such as hot‑water extraction for polysaccharides (e.g., alginates) or solvent extraction for lipids (e.g., fucoxanthin)—are then applied. The extracts are purified, filtered, and finally blended into final product formulations at concentrations ranging from 0.1 % to 5 % depending on the intended function. Who Is a Candidate? Anyone who uses skin‑care products containing brown algae‑derived ingredients can be considered a “candidate.” Particular groups that may be more attentive include: Individuals with a history of contact dermatitis or allergic skin reactions. People living in regions with high environmental arsenic exposure who wish to avoid additional sources. Consumers seeking natural or marine‑based ingredients for their perceived gentleness. Clinical Summary Procedure: Use of brown algae‑derived ingredients in cosmetic products (e.g., moisturizers, sunscreens, anti‑aging creams). Typical Duration: Continuous daily application for months to years, depending on product use. Recovery: Not applicable – these are non‑invasive topical agents. Success Rate (general): 68 of 82 evaluated ingredients were deemed safe, indicating a high overall safety profile. Study Methodology The Expert Panel performed a systematic safety review following the Cosmetic Ingredient Review (CIR) framework. The process involved collecting all publicly available toxicological data, including animal studies, human repeat‑dose trials, and in‑vitro genotoxicity assays. The panel also examined impurity reports, particularly arsenic levels, from manufacturing batches submitted by industry. Patient Selection Criteria Because the assessment focused on ingredient safety rather than patient outcomes, the panel did not enroll human participants. Instead, the “population” consisted of all available scientific studies that met pre‑specified quality criteria (e.g., peer‑reviewed, controlled, and reproducible). Outcome Measures The primary outcomes were: Identification of a NOAEL for each ingredient. Assessment of potential adverse effects such as skin irritation, sensitization, or systemic toxicity. Quantification of arsenic and other heavy‑metal impurities relative to the International Council for Harmonisation (ICH) limits. Results & Findings The panel’s review yielded the following core findings: Key Outcomes Out of 82 brown algae‑derived ingredients, 68 were judged safe for use in cosmetics at the concentrations typically employed. Commonly safe ingredients include alginic acid, fucoidan, laminarin, and various brown‑algae extracts marketed for moisturizing or antioxidant effects. For the 14 ingredients lacking sufficient data, the panel could not reach a definitive safety conclusion; manufacturers are advised to generate additional toxicology data before market entry. Arsenic was identified as the most concerning impurity. Most tested batches contained arsenic levels well below the 0.5 ppm threshold considered acceptable for cosmetics, but the panel emphasized continued vigilance. Complications & Risks While the majority of ingredients are safe, the review highlighted potential risks: Skin irritation: Some polysaccharide preparations can cause transient erythema or a mild burning sensation, especially when applied to compromised skin. Allergic sensitization: Rare cases of contact allergy to algae‑derived proteins have been reported, warranting patch‑test confirmation in susceptible individuals. Heavy‑metal exposure: In the unlikely event of elevated arsenic in a batch, prolonged use could contribute to systemic toxicity, though current manufacturing controls keep levels well under regulatory limits. Data gaps: For the 14 ingredients with insufficient data, undiscovered adverse effects cannot be ruled out, underscoring the importance of manufacturer transparency. Key Takeaways for Patients Most brown algae‑derived ingredients (68/82) are considered safe when used as instructed on product labels. Check product labels for specific ingredient names such as “alginic acid,” “fucoidan,” or “laminarin” if you prefer marine‑based actives. If you have a history of skin allergies, perform a patch test before applying a new product containing algae extracts. Ask your dermatologist whether a product has been third‑party tested for arsenic and other heavy‑metal contaminants. Be cautious with products that do not disclose the exact concentration of algae‑derived ingredients or lack a clear manufacturing source. When in doubt, request the Safety Data Sheet (SDS) from the brand to verify that the ingredient falls within the panel’s safe‑use recommendations. Frequently Asked Questions Are brown algae extracts safe for everyday use? Yes. The Expert Panel found that 68 out of 82 evaluated algae‑derived ingredients are safe at the concentrations normally used in cosmetics (Source: PubMed / Europe PMC). Can brown algae ingredients cause allergic reactions? Allergic contact dermatitis is rare but possible. If you have a history of skin allergies, perform a patch test or consult a dermatologist before regular use. What is the risk of arsenic in my moisturizer? Arsenic can be present as an impurity, but current manufacturing practices keep levels well below the 0.5 ppm limit deemed acceptable for cosmetics. Reputable brands usually test for and disclose this. How can I identify products that contain brown algae ingredients? Look for ingredient names such as alginic acid, fucoidan, laminarin, brown algae extract, or specific scientific names like Fucus vesiculosus extract on the product’s ingredient list. Should I avoid products with brown algae if I’m pregnant? There is no evidence that the approved ingredients pose a risk during pregnancy. However, if you prefer to limit exposure, choose products that explicitly state they are pregnancy‑tested or consult your obstetrician. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →
Clinical Insight

Proximal Femoral Replacement Guide

Overview Proximal femoral replacement (PFR) is a surgical procedure used to address significant bone loss in the upper part of the thigh bone, known as the proximal femur. This condition can result from various non-oncologic causes, such as severe fractures, osteonecrosis, or arthritis. According to a study published on PubMed, PFR can provide a viable solution for patients with massive proximal femoral bone loss (Source: PubMed). The study highlights the importance of understanding the outcomes and complications associated with PFR in non-oncologic cases. What This Study Examined The study focused on evaluating the functional outcomes, complications, and implant survival rates in patients who underwent PFR for non-oncologic indications. The researchers analyzed data from 30 patients who had undergone the procedure, with a mean follow-up period of 31.4 months. The study aimed to determine the efficacy of PFR in restoring limb function and alleviating symptoms in patients with significant proximal femoral bone loss. Why This Matters for Patients Understanding the outcomes and complications of PFR is crucial for patients who are considering this procedure. By analyzing the study's findings, patients can make informed decisions about their treatment options and have realistic expectations about the potential benefits and risks of PFR. Additionally, the study's results can help surgeons and healthcare providers refine their patient selection criteria and develop more effective treatment strategies for patients with non-oncologic proximal femoral bone loss. Medical Background Proximal femoral replacement is a complex surgical procedure that involves replacing the damaged or missing portion of the proximal femur with a prosthetic implant. The procedure is typically performed using a combination of osteotomy and arthroplasty. The goal of PFR is to restore the patient's hip function, alleviate pain, and improve overall mobility. How the Procedure Works The PFR procedure typically involves several steps, including the removal of the damaged bone tissue, preparation of the implant site, and insertion of the prosthetic implant. The implant is designed to mimic the natural anatomy of the proximal femur and is secured in place using a combination of bone cement and internal fixation devices. In some cases, the procedure may also involve the use of external fixators or intramedullary nails to provide additional stability to the implant. Who Is a Candidate? PFR is typically recommended for patients with significant proximal femoral bone loss due to non-oncologic causes, such as severe fractures, osteonecrosis, or arthritis. Candidates for PFR usually have significant pain, limited mobility, and compromised limb function. The procedure is often considered a salvage option for patients who have failed other treatments or have significant bone loss that cannot be addressed with other surgical procedures. Clinical Summary Procedure: Proximal femoral replacement (PFR) is a surgical procedure that involves replacing the damaged or missing portion of the proximal femur with a prosthetic implant. Typical Duration: The procedure can take several hours to complete, depending on the complexity of the case and the patient's individual needs. Recovery: The recovery period for PFR can be significant, with most patients requiring several months of physical therapy and rehabilitation to regain strength and mobility. Success Rate (general): The success rate of PFR varies depending on the individual patient and the underlying condition being treated. However, according to the study, the mean postoperative modified Harris Hip Score (mHHS) was 54.0 ± 22.4, indicating moderate functional outcomes. Study Methodology The study was a retrospective review of 63 consecutive non-oncologic PFRs performed between 2018 and 2023. After applying exclusion criteria and accounting for duplicates and patients lost to follow-up, 30 participants were available for final evaluation. The primary outcome was the postoperative mHHS, while secondary outcomes included postoperative complications, infection-free survival, and revision-free arthroplasty survival. Patient Selection Criteria The study included patients who had undergone PFR for non-oncologic indications, such as severe fractures, osteonecrosis, or arthritis. Patients with a history of oncologic conditions or those who had undergone previous hip arthroplasty were excluded from the study. Outcome Measures The study evaluated the postoperative mHHS, which is a measure of hip function and mobility. The mHHS assesses the patient's ability to perform daily activities, such as walking, climbing stairs, and getting in and out of a car. The study also evaluated postoperative complications, including periprosthetic joint infection (PJI), implant loosening, and periprosthetic fracture. Results & Findings The study found that the mean postoperative mHHS was 54.0 ± 22.4, indicating moderate functional outcomes. Male patients demonstrated higher unadjusted mHHS than females (69.2 ± 18.5 vs. 45.2 ± 19.8; p = 0.003). The study also found that the Kaplan-Meier estimated infection-free survival was 96.4% (95% CI, 89.8-100%) at 12 months, 91.4% (95% CI, 80.4-100%) at 24 months, and 73.1% (95% CI, 46.3-100%) at 60 months. Key Outcomes The study's key outcomes included the mean postoperative mHHS, infection-free survival rates, and revision-free arthroplasty survival rates. The study found that the mean postoperative mHHS was moderate, indicating that patients achieved some improvement in hip function and mobility. However, the study also found that complications, including PJI and implant loosening, were common, occurring in 50% of patients. Complications & Risks The study found that overall complications occurred in 15 patients (50%), with PJI being the most frequent (n = 4, 13.3%). Other complications included implant loosening, periprosthetic fracture, and neurological injury. The study highlights the importance of careful patient selection, meticulous surgical technique, and close postoperative monitoring to minimize the risk of complications. Key Takeaways for Patients PFR can provide moderate functional outcomes and alleviate symptoms in patients with significant proximal femoral bone loss. The procedure is associated with a risk of complications, including PJI, implant loosening, and periprosthetic fracture. Patient selection, surgical technique, and postoperative care are critical factors in determining the success of PFR. Patients should discuss their individual risks and benefits with their surgeon and have realistic expectations about the potential outcomes of PFR. Patients should ask their surgeon about the following: The potential benefits and risks of PFR The expected recovery period and rehabilitation requirements The likelihood of complications and the plan for managing them The potential need for revision surgery Frequently Asked Questions What is proximal femoral replacement? Proximal femoral replacement (PFR) is a surgical procedure that involves replacing the damaged or missing portion of the proximal femur with a prosthetic implant. The goal of PFR is to restore hip function, alleviate pain, and improve overall mobility. Who is a candidate for PFR? PFR is typically recommended for patients with significant proximal femoral bone loss due to non-oncologic causes, such as severe fractures, osteonecrosis, or arthritis. Candidates for PFR usually have significant pain, limited mobility, and compromised limb function. What are the potential complications of PFR? The potential complications of PFR include periprosthetic joint infection (PJI), implant loosening, periprosthetic fracture, and neurological injury. The study found that overall complications occurred in 50% of patients, with PJI being the most frequent. What is the expected recovery period for PFR? The recovery period for PFR can be significant, with most patients requiring several months of physical therapy and rehabilitation to regain strength and mobility. The study found that the mean follow-up period was 31.4 months, indicating that patients may require ongoing care and monitoring for an extended period. Can PFR be revised if complications occur? Yes, PFR can be revised if complications occur. The study found that revision-free arthroplasty survival rates were 85.1% (95% CI, 68%, 100%) at 12 and 24 months, and 49.7% (95% CI, 25.6-96.3%) at 60 months, indicating that some patients may require revision surgery to address complications or implant failure. Related Articles Sickle Cell Disease & Septic Nonunion Limb Lengthening & Nonunion Treatment

Read Full Summary →